ZGNX (ZGNX) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ZGNX (ZGNX) ist an US-Boersen notiert, zuletzt bei $26.67 mit einer Marktkapitalisierung von 0. Die Aktie erreicht einen hohen Ueberzeugungsscore von 71/100 ueber fundamentale, technische und Stimmungsfaktoren.
Zuletzt analysiert: 21. Jan. 2026ZGNX Unternehmensueberblick
Zogenix, Inc. aims to transform the lives of patients with rare diseases through Fintepla, a promising therapy despite the company's current unprofitability and lack of analyst coverage.
Investmentthese
Zogenix presents a high-risk, high-reward investment opportunity. While the company's -278.4% net margin is concerning, potential growth catalysts include successful clinical trials and expanded indications for Fintepla. A strong competitive moat could be established if Fintepla becomes the standard of care for Dravet and Lennox-Gastaut syndromes.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wettbewerber & Vergleichsunternehmen
Staerken
- High gross margin (94.1%) indicates strong pricing power
- Focus on rare diseases provides a niche market
- Current ratio of 3.63 indicates strong liquidity
Schwaechen
- Extremely negative operating and net margins (-259.6% and -278.4%)
- Lack of analyst coverage increases uncertainty
- Zero market cap suggests significant financial distress
Katalysatoren
- Upcoming: Phase III clinical trial results for Fintepla in Lennox-Gastaut syndrome (Q4 2026)
- Ongoing: Expansion of Fintepla's label to include other rare epileptic syndromes
Risiken
- Valuation risk due to negative earnings and lack of market cap
- Operational risk associated with clinical trials and regulatory approvals
- Market risk associated with competition and pricing pressures
Wachstumschancen
- Expansion of Fintepla's label to include other rare epileptic syndromes (ongoing)
- Successful Phase III clinical trial results for Fintepla in Lennox-Gastaut syndrome (2026)
- Commercialization of MT1621 for other rare diseases (2027+)
- Partnerships with larger pharmaceutical companies for distribution and commercialization (ongoing)
Chancen
- Potential for Fintepla to become the standard of care for Dravet and Lennox-Gastaut syndromes
- Expansion into new geographic markets
- Development of new therapies for other rare diseases
Risiken
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Market risk associated with rare disease therapeutics
Wettbewerbsvorteile
- Potential for intellectual property protection on Fintepla
- Orphan drug designation provides market exclusivity
Ueber ZGNX
Zogenix, Inc., founded in 2010 and headquartered in Emeryville, CA, is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. With a team of 327 employees, the company's primary focus is Fintepla, a low-dose fenfluramine treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Despite a $0M market cap, Zogenix aims to establish a strong market position by addressing unmet needs in rare epileptic syndromes. The company also has MT1621 in development, targeting other rare diseases. Zogenix operates primarily in the United States, seeking to expand its reach through clinical trials and potential partnerships.
Was das Unternehmen tut
- Develop and commercialize therapies for rare diseases
- Conduct clinical trials to evaluate the safety and efficacy of their products
- Seek regulatory approvals from the FDA and other regulatory agencies
Geschaeftsmodell
- Sales of Fintepla
- Potential for licensing agreements with other pharmaceutical companies
- Government grants and funding for research and development
Wichtige Kunden
- Patients with Dravet syndrome
- Patients with Lennox-Gastaut syndrome
- Healthcare providers specializing in epilepsy treatment
Finanzdaten
Chart & Info
ZGNX (ZGNX) Aktienkurs: $26.67 (+0.41, +1.54%)
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Friday
· 20. Aug. 2021
-
Stocks That Hit 52-Week Lows On Thursday
· 27. Feb. 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· 26. Feb. 2020
-
Stocks That Hit 52-Week Lows On Monday
· 10. Feb. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ZGNX.
Kursziele
Wall-Street-Kurszielanalyse fuer ZGNX.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ZGNX auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Was Anleger ueber ZGNX (ZGNX) wissen wollen
What are the key factors to evaluate for ZGNX?
ZGNX (ZGNX) currently holds an AI score of 71/100, indicating high score. With a beta of 0.90, ZGNX is roughly in line with the broader market. The company maintains a 94% gross margin. Key strength: High gross margin (94.1%) indicates strong pricing power. Primary risk to monitor: Valuation risk due to negative earnings and lack of market cap. This is not financial advice.
How frequently does ZGNX data refresh on this page?
ZGNX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ZGNX's recent stock price performance?
Recent price movement in ZGNX (ZGNX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. With a beta of 0.90, ZGNX tends to move roughly in line with the broader market. Notable catalyst: High gross margin (94.1%) indicates strong pricing power. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ZGNX overvalued or undervalued right now?
Determining whether ZGNX (ZGNX) is overvalued or undervalued requires examining multiple metrics. Gross margin is 94%. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ZGNX?
Before investing in ZGNX (ZGNX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ZGNX to a portfolio?
Potential reasons to consider ZGNX (ZGNX) depend on individual investment goals and risk tolerance. A key strength identified by analysis: High gross margin (94.1%) indicates strong pricing power. Additionally: Focus on rare diseases provides a niche market. The AI-driven MoonshotScore of 71/100 reflects strong quantitative fundamentals. A 94% gross margin indicates meaningful pricing power. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ZGNX?
Yes, most major brokerages offer fractional shares of ZGNX (ZGNX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ZGNX's earnings and financial reports?
ZGNX (ZGNX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ZGNX earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of October 2023.